U87-MG Xenograft Rat Model Service for Brain Cancer

The U87-MG xenograft rat model stands as one of the most extensively characterized systems for studying glioblastoma multiforme (GBM), offering researchers a reliable platform to evaluate therapeutic candidates in a physiologically relevant intracranial environment. At Alfa Cytology, we specialize in constructing and managing high-fidelity U87-MG xenograft rat models tailored to your preclinical study objectives, delivering consistent tumor kinetics and comprehensive endpoint analyses that advance your oncology pipeline from early proof-of-concept through late-stage candidate selection.

Overview of U87-MG Xenograft Rat Model for Brain Cancer

The U87-MG cell line was originally established in 1968 by Ponten and colleagues at Uppsala University from a surgical specimen obtained from a 44-year-old female patient diagnosed with glioblastoma multiforme. Over the subsequent decades, this cell line has evolved into the most frequently employed human glioblastoma model in neuro-oncology research, forming the backbone of thousands of preclinical investigations spanning drug screening, angiogenesis studies, and imaging modality development. When propagated as an orthotopic xenograft within the rat brain, U87-MG cells recapitulate several hallmark features of human GBM, most notably the formation of densely vascularized tumor masses driven by constitutive activation of the PI3K/Akt signaling axis following homozygous deletion of the PTEN tumor suppressor gene. Unlike patient-derived GBMs that often display diffuse infiltration into surrounding parenchyma, U87-MG xenografts tend to grow as well-circumscribed lesions with pronounced neovascularization, a phenotype that has proven exceptionally valuable for testing anti-angiogenic agents and evaluating blood-brain barrier penetration of novel therapeutics.

Fig 1. Characteristics of tumor-associated microglial responses to U87 human glioblastoma xenografts. (Dugandžija, Tihomir, et al., 2021)

In the rat orthotopic setting, the larger cranial vault and more substantial brain volume relative to mice afford distinct technical advantages, including enhanced precision during stereotactic cell implantation, improved spatial resolution for longitudinal imaging, and greater tissue availability for downstream histopathological and molecular analyses. U87-MG tumors in this context typically establish within 2–3 weeks post-implantation and demonstrate predictable growth kinetics, with median survival windows that can be modulated by adjusting initial cell inoculum density. The model's genetic profile—encompassing wild-type TP53, methylated MGMT promoter rendering sensitivity to alkylating agents, and deletion of cell-cycle regulators such as CDKN2A—mirrors the molecular landscape observed in a substantial subset of human GBM patients, thereby supporting translational relevance for therapeutic efficacy assessments.

Cell Line Information: U87-MG

The U87-MG cell line represents a cornerstone resource in glioblastoma research, with a well-documented provenance and extensively characterized molecular phenotype. Originally isolated from a human glioblastoma surgical specimen, this adherent epithelial-like cell population has been distributed globally through major biorepositories and remains among the most cited models in neuro-oncology literature. The following table summarizes the essential characteristics of the U87-MG cell line as utilized in preclinical xenograft applications.

Our Services

Alfa Cytology brings deep expertise in neuro-oncology preclinical model development, offering end-to-end U87-MG xenograft rat model services that span study design, stereotactic surgical implantation, longitudinal tumor monitoring, and terminal necropsy with multi-parameter tissue characterization. Our team understands that every brain cancer therapeutic program carries unique analytical requirements—whether your focus lies in small-molecule blood-brain barrier penetration, biologic distribution, or combination regimen scheduling—and we architect each study protocol to generate decision-quality data that withstands rigorous scientific scrutiny.

Workflow of U87-MG Xenograft Rat Model Construction

Construction of an orthotopic U87-MG xenograft rat model demands meticulous attention to surgical precision, cell viability, and post-operative care to ensure reproducible tumor formation and valid pharmacological readouts. The workflow outlined below reflects the standardized protocol employed at Alfa Cytology for generating reliable intracranial glioblastoma xenografts in immunodeficient rat hosts, with each phase optimized to minimize procedural variability and maximize translational fidelity.

1. Cell Preparation and Quality Control: U87-MG cells are expanded under standardized culture conditions and harvested during exponential growth phase using trypsin-EDTA dissociation. Cell viability is assessed by trypan blue exclusion, with only preparations exceeding 95% viability accepted for implantation. The single-cell suspension is concentrated to the desired density—typically 1 × 10⁶ cells in 5 μL sterile PBS—proceeding to implantation.
2. Animal Selection and Acclimation: Immunodeficient nude rats (e.g., Hsd:Rh-rnu) aged 8–10 weeks are obtained from accredited vendors and allowed a minimum 7-day acclimation period within our AAALAC-accredited vivarium. Animals are group-housed under controlled environmental conditions (12:12 light-dark cycle, 22 ± 2°C, 55–65% relative humidity) with ad libitum access to sterilized food and water.
3. Anesthesia and Surgical Preparation: Rats are anesthetized using a ketamine-xylazine cocktail administered via intraperitoneal injection, with depth of anesthesia confirmed by loss of pedal withdrawal reflex. The surgical site is prepared by clipping cranial fur and performing a three-step sterile scrub alternating povidone-iodine and 70% ethanol. Ophthalmic ointment is applied to prevent corneal desiccation during the procedure.
4. Stereotactic Intracranial Injection: The anesthetized rat is secured in a stereotactic frame with ear bars and incisor bar aligned to maintain a flat skull position. A midline scalp incision exposes the cranium, and a burr hole is drilled at predetermined coordinates relative to bregma (typically anterior-posterior +1.0 mm, mediolateral +2.5 mm, dorsoventral −4.5 mm for striatal targeting in a 250–300 g rat). A Hamilton microsyringe fitted with a 26-gauge needle is lowered to the target depth, and the cell suspension is infused at a controlled rate of 1 μL/min over 5 minutes. The needle is retained in situ for an additional 2 minutes post-injection to prevent backflow, then withdrawn slowly.
5. Wound Closure and Post-Operative Monitoring: The burr hole is sealed with sterile bone wax, the scalp is closed with surgical sutures or wound clips, and povidone-iodine is reapplied. Animals are placed on a heated recovery pad and monitored every 15 minutes until ambulatory. Buprenorphine is administered for analgesia according to IACUC-approved protocols. Diet gel and softened food are provided for 72 hours post-surgery to encourage nutritional intake during recovery.
6. Tumor Monitoring and Study Execution: Tumor establishment and progression are monitored through a combination of palpation (where applicable for flank models), MRI or bioluminescence imaging for orthotopic lesions, and neurological behavioral assessments. Body weights are recorded thrice weekly, and animals are examined daily for signs of pain, distress, or neurological deficit. Dosing regimens are initiated once tumors reach predetermined volume or imaging signal thresholds, with treatment arms randomized to ensure statistical balance.
7. Necropsy and Tissue Collection: At study termination—defined by protocol-specified endpoints such as maximal tumor burden, significant weight loss (>20%), or neurological morbidity—animals are humanely euthanized. Brains are extracted, photographed, and sectioned coronally using a brain matrix. Tumor tissue and contralateral brain are allocated for formalin-fixed paraffin embedding (FFPE), snap-freezing in liquid nitrogen, or stabilization in RNAlater, depending on downstream analytical requirements. Serum and plasma samples are collected for pharmacokinetic profiling.

Fig 2. U87-MG Xenograft Rat Model construction workflow.

Case Study-U87-MG Xenograft Rat Model Development

In a recent preclinical engagement, Alfa Cytology established an orthotopic U87-MG xenograft cohort in nude rats to evaluate the intracranial efficacy of a novel PI3K/Akt pathway inhibitor formulated for enhanced blood-brain barrier traversal. Following stereotactic implantation of 1 × 10⁶ U87-MG cells, animals were randomized into vehicle control and treatment arms once bioluminescence imaging confirmed robust tumor engraftment. The study incorporated longitudinal MRI assessments at weekly intervals to quantify tumor volume dynamics, complemented by terminal histopathological examination featuring H&E staining, CD31 immunohistochemistry for microvessel density quantification, and TUNEL assays for apoptotic index determination. Pharmacokinetic sampling at multiple time points enabled correlation of plasma and brain tissue drug concentrations with anti-tumor activity, yielding a comprehensive dataset that supported the sponsor's Investigational New Drug (IND)-enabling package. All procedures were conducted under preclinical Good Laboratory Practice (GLP) standards with full IACUC oversight.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your U87-MG xenograft rat model program means gaining access to a scientifically rigorous, operationally agile CRO that treats every study as a collaborative endeavor. Our differentiated capabilities in neuro-oncology preclinical research translate into faster timelines, higher data integrity, and greater confidence in your go/no-go decisions.

• Neuro-oncology specialization with dedicated surgical teams experienced in rodent stereotactic intracranial procedures, ensuring precise cell placement and minimal perioperative mortality.
• In-house imaging infrastructure including small-animal MRI, bioluminescence imaging (BLI), and micro-CT, enabling non-invasive longitudinal tumor monitoring without sacrificing statistical power.
• Customizable study designs that accommodate single-agent efficacy, combination therapy scheduling, dose-escalation paradigms, and pharmacokinetic/pharmacodynamic (PK/PD) integration.
• Comprehensive histopathology and molecular pathology services encompassing H&E, IHC, IF, RNAscope, and digital image analysis, all performed within our integrated laboratory network.
• Strict adherence to animal welfare regulations with AAALAC-accredited facilities, IACUC-approved protocols, and veterinary staff present throughout all surgical and post-operative phases.
• Dedicated project management ensuring transparent communication, milestone-driven reporting, and rapid adaptation to emerging data or sponsor-directed protocol amendments.
• Competitive turnaround times from study initiation to final report delivery, supported by streamlined operational workflows and established relationships with certified animal vendors and reagent suppliers.

Contact Us

Whether you are advancing a first-in-class glioblastoma therapeutic or refining the preclinical strategy for an established oncology asset, Alfa Cytology is ready to support your program with expertly executed U87-MG xenograft rat model services. Reach out to us today to discuss your study requirements, review our capabilities deck, or request a customized proposal tailored to your specific research objectives. Our scientific team looks forward to collaborating with you to generate the high-quality preclinical data your program demands.

For research use only. Not intended for any clinical use.